Modifying effect of arterial hypertension on amyotrophic lateral sclerosis
暂无分享,去创建一个
Philippe Amouyel | Luc Defebvre | Alain Duhamel | Caroline Moreau | David Devos | Régis Bordet | L. Defebvre | A. Destée | P. Amouyel | R. Bordet | J. Dallongeville | D. Devos | A. Duhamel | C. Moreau | F. Richard | J. De Reuck | Jean Dallongeville | Florence Richard | Alain Destée | T. Pérez | V. Brunaud-Danel | L. Laurier-Grymonprez | Anne Charlotte Wiart | Véronique Brunaud-Danel | Laurence Laurier-Grymonprez | Jacques de Reuck | Thierry Perez | T. Perez
[1] D. Arveiler,et al. High blood pressure prevalence and control in a middle-aged French population and their associated factors: the MONA LISA study , 2011, Journal of hypertension.
[2] P. Carmeliet,et al. VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model , 2004, Nature.
[3] L. Defebvre,et al. Paradoxical response of VEGF expression to hypoxia in CSF of patients with ALS , 2006, Journal of Neurology, Neurosurgery & Psychiatry.
[4] M. Polkey,et al. Respiratory muscle strength and ventilatory failure in amyotrophic lateral sclerosis. , 2001, Brain : a journal of neurology.
[5] Till Acker,et al. Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration , 2001, Nature Genetics.
[6] J. LaManna,et al. Structural and functional adaptation to hypoxia in the rat brain , 2004, Journal of Experimental Biology.
[7] A. Al-Chalabi,et al. Early symptom progression rate is related to ALS outcome: a prospective population-based study. , 2002, Neurology.
[8] T. Hanafusa,et al. Progression rate of ALSFRS-R at time of diagnosis predicts survival time in ALS , 2006, Neurology.
[9] P. Carmeliet,et al. VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death , 2003, Nature Genetics.
[10] F. Fazekas,et al. Prevalence of White Matter and Periventricular Magnetic Resonance Hyperintensities in Asymptomatic Volunteers , 1991 .
[11] F. Norris,et al. Onset, natural history and outcome in idiopathic adult motor neuron disease , 1993, Journal of the Neurological Sciences.
[12] V. Sébille,et al. Rural environment and risk factors of amyotrophic lateral sclerosis: a case–control study , 2010, Journal of Neurology.
[13] G. Chatellier,et al. Prevalence and Therapeutic Control of Hypertension in 30 000 Subjects in the Workplace , 2001, Hypertension.
[14] A. Chiò,et al. Severely increased risk of amyotrophic lateral sclerosis among Italian professional football players. , 2005, Brain : a journal of neurology.
[15] L. Defebvre,et al. CSF profiles of angiogenic and inflammatory factors depend on the respiratory status of ALS patients , 2009, Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases.
[16] S. Harding. Complications and consequences of obstructive sleep apnea , 2000, Current opinion in pulmonary medicine.
[17] M Schumacher,et al. A bootstrap resampling procedure for model building: application to the Cox regression model. , 1992, Statistics in medicine.
[18] J. C. Torre,et al. Evidence that Alzheimer’s disease is a microvascular disorder: the role of constitutive nitric oxide , 2000, Brain Research Reviews.
[19] A. Eisen,et al. Duration of amyotrophic lateral sclerosis is age dependent , 1993, Muscle & nerve.
[20] D. Sautereau,et al. Nutritional status is a prognostic factor for survival in ALS patients , 1999, Neurology.
[21] H. Ehrenreich,et al. Soccer, neurotrauma and amyotrophic lateral sclerosis: is there a connection? , 2004, Current medical research and opinion.
[22] L. H. van den Berg,et al. Beneficial vascular risk profile is associated with amyotrophic lateral sclerosis , 2011, Journal of Neurology, Neurosurgery & Psychiatry.
[23] Sakurai,et al. Expression of angiogenic factors in rabbit spinal cord after transient ischaemia , 1999, Neuropathology and applied neurobiology.
[24] C. Visser,et al. Amyotrophic lateral sclerosis: mortality risk during the course of the disease and prognostic factors , 1997, Journal of the Neurological Sciences.
[25] T. Hanafusa,et al. Progression rate of ALSFRS-R at time of diagnosis predicts survival time in ALS , 2006, Neurology.
[26] F. Clavel-Chapelon,et al. Smoking and risk for amyotrophic lateral sclerosis: Analysis of the EPIC cohort , 2009, Annals of neurology.
[27] Jack A. Taylor,et al. VEGF PROMOTER HAPLOTYPE AND AMYOTROPHIC LATERAL SCLEROSIS (ALS) , 2004, Journal of neurogenetics.
[28] C. Desnuelle,et al. [Epidemiology of amyotrophic lateral sclerosis]. , 2009, Revue neurologique.
[29] T D Koepsell,et al. Prognosis in amyotrophic lateral sclerosis , 2003, Neurology.
[30] A. Ludolph,et al. Amyotrophic lateral sclerosis. , 2012, Current opinion in neurology.
[31] Sleep disorders and diaphragmatic function in patients with amyotrophic lateral sclerosis. , 2000, American journal of respiratory and critical care medicine.
[32] L. Defebvre,et al. Deregulation of the hypoxia inducible factor-1α pathway in monocytes from sporadic amyotrophic lateral sclerosis patients , 2011, Neuroscience.
[33] D. Leys,et al. The impact of cerebral amyloid angiopathy on the occurrence of cerebrovascular lesions in demented patients with Alzheimer features: a neuropathological study , 2011, European journal of neurology.
[34] S H Appel,et al. Natural history of amyotrophic lateral sclerosis in a database population. Validation of a scoring system and a model for survival prediction. , 1995, Brain : a journal of neurology.
[35] V. Meininger,et al. SOD1, ANG, VAPB, TARDBP, and FUS mutations in familial amyotrophic lateral sclerosis: genotype–phenotype correlations , 2010, Journal of Medical Genetics.
[36] S. Bourke,et al. Respiratory function vs sleep-disordered breathing as predictors of QOL in ALS , 2001, Neurology.
[37] J. Iłżecka. Cerebrospinal fluid vascular endothelial growth factor in patients with amyotrophic lateral sclerosis , 2004, Clinical Neurology and Neurosurgery.
[38] Lorene M. Nelson,et al. Epidemiology of ALS. , 1995, Clinical neuroscience.
[39] D. Arveiler,et al. Trends in plasma lipids, lipoproteins and dyslipidaemias in French adults, 1996-2007. , 2009, Archives of cardiovascular diseases.
[40] A. Destée,et al. Low levels of the vascular endothelial growth factor in CSF from early ALS patients , 2004, Neurology.
[41] S. Ennis,et al. ANG mutations segregate with familial and 'sporadic' amyotrophic lateral sclerosis , 2006, Nature Genetics.
[42] T. Perez. Sclrose latrale amyotrophique (SLA) : valuation des fonctions ventilatoires , 2006 .